{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-004649","form_type":"8-K","ticker":"EDSA","cik":"0001540159","company_name":"Edesa Biotech, Inc.","filed_at":"2024-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.456039+00:00","generated_at":"2026-05-31T10:23:08.754226+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edesa Biotech reports Q3 net loss $1.7M; ARDS drug selected for U.S. government study","bullets":["Net loss of $1.7M ($0.52/shr) vs $2.0M ($0.68/shr) a year ago; nine-month loss $5.2M ($1.64/shr).","Cash $2.0M; working capital $0.7M; received $300K post-quarter from Canadian govt SIF fund.","EB05 (paridiprubart) chosen for HHS-funded ARDS platform study; Edesa supplies drug and tech support.","Preparing IND for Phase 2 vitiligo study of anti-CXCL10 technology in moderate-to-severe patients.","Q3 operating expenses $1.9M, down $0.2M YoY; R&D $0.9M, down $0.1M."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-004649","json":"https://secwatch.observer/filing/0001171843-24-004649.json","markdown":"https://secwatch.observer/filing/0001171843-24-004649.md","text":"https://secwatch.observer/filing/0001171843-24-004649.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/0001171843-24-004649-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1540159/000117184324004649/f8k_080924.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T10:23:08.754226+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}